Annual Fractional Exhaled Nitric Oxide Measurements and Exacerbations in Severe Asthma

This article was published in the following Dove Press journal: 
Journal of Asthma and Allergy

Yuki Abe
Masaru Suzuki
Hirokazu Kimura
Kaoruko Shimizu
Hironi Makita
Masaharu Nishimura
Satoshi Konno
Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan

Purpose: Fractional exhaled nitric oxide (FENO) reflects eosinophilic inflammation of the airways. However, the significance of longitudinal assessment of FENO, including its variability, in the clinical course of severe asthma remains unclear. The aim of this study is to examine the association between long-term changes in FENO and the development of exacerbations in severe asthma.

Patients and Methods: Among the severe asthma patients enrolled in the Hokkaido Severe Asthma Cohort Study, 100 patients with severe asthma who completed a 3-year follow-up in which FENO was measured annually were included. According to the FENO level at baseline, 1 year, and 2 years, the patients were classified into three groups: the sustained high group (≥50 ppb at all three visits), the sustained low group (<25 ppb at all three visits), and the intermediate group (other). Subjects in the intermediate group were further classified into two groups based on the median value of the coefficient of variation (CV) of FENO during the 3 years (high CV and low CV intermediate groups).

Results: The sustained high group experienced shorter exacerbation-free survival and more frequent exacerbations than the sustained low group (median number of exacerbation events, 3 vs 0, p = 0.01). In the intermediate group, the high CV group experienced shorter exacerbation-free survival than the low CV group, and the CV of FENO was an independent contributing factor to the development of exacerbations.

Conclusion: Persistence of FENO above 50 ppb over the years as well as the presence of large variations in FENO levels was associated with the development of exacerbations in patients with severe asthma.

Keywords: asthma, coefficient of variation, exacerbation, fractional exhaled nitric oxide, longitudinal assessment, variability

Introduction

Some patients with severe asthma remain uncontrolled despite good adherence to high-dose inhaled corticosteroids (ICS) and treatment of contributory factors; severe asthma also places a major health and economic burden. There are at least two distinct subgroups in asthma: high expression of type 2 cytokines associated with eosinophilic airway inflammation and low expression of type 2 cytokines associated with neutrophilic airway inflammation. Severe asthma is heterogeneous, and distinct phenotypes have been recognized even in cigarette smokers with severe asthma. On the other hand, non-invasive measurement of fractional exhaled nitric oxide (FENO) reflects eosinophilic inflammation in the lower respiratory tract. Nitric oxide is generated in the airways by inducible nitric oxide synthase (iNOS or NOS-2), which is mediated by type 2 cytokines, such as
interleukin (IL)-4 and IL-13.\(^5\) Although iNOS is generally expressed in activated cells, it is also constitutively expressed not only in inflammatory state.\(^6\) FENO is associated with the levels of eosinophils in the airway mucosa, bronchoalveolar lavage fluid, sputum, and blood;\(^7,8\) thus, FENO levels are high in patients with asthma characterized by type 2 inflammation.\(^9\) High FENO levels have also been reported to be associated with good short-term response to ICS.\(^10,11\) We previously reported that in patients with severe asthma, FENO at baseline had a potential to predict future exacerbations.\(^12\) However, since asthma is a chronic disease with variable symptoms and clinical course, longitudinal assessment of biomarkers would be more significant than baseline assessment alone, and the significance of annual longitudinal assessment of FENO, including its variability, in the clinical course of severe asthma, especially the development of exacerbations, remains unclear. We hypothesized that fluctuation of FENO levels on an annual basis might be associated with the development of exacerbations in patients with severe asthma.

The Hokkaido Severe Asthma Cohort Study or the Hokkaido-based Investigative Cohort Analysis for Refractory Asthma (Hi-CARAT) is a multicenter observational cohort study that primarily aimed to characterize patients with severe asthma, including smokers. We completed a 3-year follow-up with annual assessments of FENO and other clinical parameters. In this study, we retrospectively examined the association of annual longitudinal measurements in FENO levels and the development of exacerbations in a 3-year observational cohort of patients with severe asthma.

**Patients and Methods**

**Study Protocol and Participants**

The study is based on data from the Hokkaido Severe Asthma Cohort Study (Hi-CARAT), which has previously been described in detail.\(^12,13\) Patients with severe asthma were enrolled from Hokkaido University Hospital (Sapporo, Japan) and 29 affiliated hospitals and clinics between February 2010 and September 2012. This study was conducted in accordance with the Declaration of Helsinki, and ethical approval for conducting this study was obtained from the Institutional Review Board of Hokkaido University Hospital (reference number: 009-0025). This study was approved by the ethics committees of all hospitals, and all subjects provided written informed consent. This study was registered in the University Hospital Medical Information Network Center Clinical Trials Registry system (https://upload.umin.ac.jp/cgi-open-bin/ctrctr_view.cgi?recptno=R000003917). The diagnosis of severe asthma is based on the American Thoracic Society (ATS) criteria for refractory asthma published in 2000,\(^14\) with slight modifications.\(^3,12,13\) Once patients were well controlled under current medications, they were asked if within 1 year they experienced episodic deterioration of symptoms, urgent care visits, and rescue use of short-acting bronchodilators when the dose of the current medication was reduced, in order to consider them as having severe asthma. Participants stayed at Hokkaido University Hospital for 2 days for initial screening and were followed up every 1 year on an outpatient basis for 3 years. Before initial screening, subjects were asked to demonstrate adherence to all drugs using a 4-week self-monitoring diary. Subjects with poor medication adherence to their medications and inadequate medication inhalation technique were excluded, and a total of 127 subjects with severe asthma were included in the baseline analysis. During the follow-up period, all subjects were asked to record their medication use for 4 weeks per season (for a total of 16 weeks per year) in their asthma diaries to assess medication adherence. Patients also visited at each hospital and clinic every 1–2 months, and their medication adherence and inhalation technique were checked by their physician each time. Subjects with low adherence (<70%) were excluded from the final analysis.

**FENO Measurement**

FENO levels were measured using the single-breath online method with NIOX MINO (Aerocrin, Stockholm, Sweden) according to the ATS guidelines.\(^10\) FENO levels were measured four times: at the initial screening at visit entry (VE), 1 year later (V1), 2 years later (V2), and 3 years after VE (V3). Detailed measurements of other biomarkers have been described in detail in previous reports.\(^3,12,13\)

**Assessment of Exacerbation**

Asthma exacerbation was defined as the need for systemic corticosteroids for more than 3 days and/or hospital admission, corresponding to “severe exacerbation” based on the European Respiratory Society/ATS guidelines for severe asthma.\(^15\)
Statistical Analysis
Descriptive statistics of patient characteristics within the cohort were calculated. Continuous variables were summarized using mean and standard deviation for continuous parametric variables, and median and interquartile range (difference between the 25th and 75th percentiles) for continuous non-parametric variables. The individual coefficients of variation (CV) of FENO levels were calculated by dividing the standard deviation of FENO from each VE to V3 by the average value. To examine the differences among groups, we used the Chi-square test for categorical variables, the Student’s t-test or one-way analysis of variance for continuous parametric variables, and the Mann–Whitney U-test or Kruskal–Wallis test for continuous non-parametric variables. Post-hoc Dunn’s test was used for non-parametric multiple comparisons. Factors associated with exacerbation-free survival were analyzed using the Cox proportional hazards model and the Kaplan–Meier method with the Log-rank test. Factors associated with the frequency of exacerbation were analyzed using the Poisson regression model. Results were presented as hazard ratios and 95% confidence intervals (CIs). For cluster analysis, a hierarchical clustering method was performed. Statistical significance was defined as p <0.05. Statistical analyses were performed using JMP (SAS Institute Inc., Cary, NC, USA) and EZR version 1.42 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R software (The R Foundation for Statistical Computing, Vienna, Austria).16

Results
Demographic Characteristics of the Subjects
A flow chart demonstrating the study process from the initial screening at visit entry (VE) to 1 year later (V1), 2 years later (V2), and 3 years after VE in the follow-up period (V3) is shown in Figure 1. Altogether, 100 subjects with severe asthma whose FENO levels were measured at all visits of VE, V1, and V2 were analyzed in this study. The characteristics of the 100 subjects are shown in Table 1. The average age at registration was 58.5 ± 12.2 years; 58% of the patients were female (n = 58) and 61% were atopic (n = 61). Twelve (12%) of the subjects were current smokers and 51 (51%) were ex-smokers, and the mean number of years since cessation among ex-smokers was 15.7 ± 11.5 (standard deviation) years. Thirty-seven subjects (37%) used daily oral corticosteroids (OCS). The median FENO at baseline (VE) was 27.5 ppb (range, 17.0–47.5 ppb). During the 3-year follow-up period, 59 subjects (59%) experienced at least one exacerbation, and the median number of exacerbation events was 1.5 (interquartile range, 0–4).

Annual Changes in FENO
We used FENO values at 25 ppb and 50 ppb as thresholds indicating low and high levels of FENO based on the ATS guidelines.10 As shown in Figure 2, 24% of the subjects had FENO levels of 50 ppb or greater at baseline (VE); 50% of them still had FENO level of at least 50 ppb after 1 year (V1), and 75% of them had sustained FENO level of at least 50 ppb after 2 years (V2). On the other hand, 47% of the subjects had FENO levels less than 25 ppb at baseline. Approximately 85% of them still had FENO levels lower than 25 ppb after 1 year, and 83% of them had FENO less than 25 ppb after 2 years.

We classified the subjects into three groups according to FENO values at VE, V1, and V2: (1) the sustained high group (≥50 ppb at all three visits), (2) the sustained low group (<25 ppb at all three visits), and (3) the intermediate group, which did not meet any of the two aforementioned criteria. Nine (9%) subjects were classified into the sustained high group, 33 (33%) into the sustained low group, and 58 (58%), intermediate group. After 3 years (V3), 88% of the sustained high group had FENO ≥50 ppb and 83% of the sustained low group had FENO <25 ppb (Figure 2).

As shown in Table 1, the use of regular OCS was significantly more frequent in the sustained high group, and the prevalence of sinusitis was low in the sustained low group. Overall exacerbation events during the 3-year follow-up period were more frequent in the sustained high group than in the sustained low group (median number of exacerbation events, 3 [interquartile range (IQR) 1.5–14.5] vs 0 [IQR 0–2], p = 0.01, Figure 3).

Analysis of the Intermediate Group
We calculated the individual CV of FENO levels from VE to V3 for subjects in the intermediate group. The median CV of subjects in the intermediate group was 0.335 [range 0.200–0.520], and the intermediate group was classified into two groups: one higher than the median (high CV, n=29) and one lower than the median (low CV, n=29). Table 2 shows the clinical characteristics of the two groups. There were no significant differences in age,
body mass index, or pulmonary function test results between the two groups. The asthma control test score, asthma quality of life questionnaire score, and score for sinusitis (Lund–Mackay score) also did not differ between the two groups. The smoking (pack-years) and depression scores (Self-Rating Depression Scale) were significantly higher in the high CV intermediate group than in the latter. The number of atopic subjects and the daily dose of ICS tended to be higher in the high CV intermediate group, although these did not reach statistical significance. Moreover, exacerbation-free survival was shorter in the high CV intermediate group than in the low CV intermediate group (Figure 4). The Kaplan–Meier curve for exacerbation-free survival of the high CV intermediate group was similar to that of the sustained high group, and the Kaplan–Meier curve of the low CV intermediate group was similar to that of the sustained low group (p = 0.03, Log-rank test among the four groups) (Figure 4). When subjects in the high CV intermediate group were classified into two groups based on the pattern of FENO variation by cluster analysis (Figure 5), the peak of FENO in one group was VN and the other was V2. There was no difference in exacerbation-free survival among the clustered groups; most of the subjects in the high CV intermediate group experienced their first exacerbation within 1 year (Figure 6).

In the intermediate group, the multivariate Cox proportional hazards model showed that the CV of FENO was a significant and independent risk factor for the early onset of the first exacerbation event (Table 3). Furthermore, the
multivariate Poisson regression model showed that blood eosinophil count and CV of FENO were significantly associated with exacerbation frequency during the follow-up period (Table 3).

## Discussion
We examined the association of annual longitudinal measurements in FENO with the development of exacerbation in severe asthma using data from the Hokkaido Severe Asthma Cohort Study (Hi-CARAT), a prospective cohort study. We found that persistence of FENO levels above 50 ppb over the years was associated with the development of exacerbations in patients with severe asthma. In addition, even if the FENO level was not sustainably above 50 ppb, the large variation in FENO levels was associated with the development of exacerbations.

FENO has been found to reflect eosinophilic inflammation in the airways of asthmatic patients. Previous studies have also supported FENO’s role in reflecting asthma control and as a biomarker of response to ICS therapy.

### Table 1 Characteristics of Subjects at Baseline by Group, Based on Changes in FENO Over Three Years

| Demographics | All Patients | Sustained Low | Intermediate | Sustained High | P-value |
|---------------|--------------|---------------|--------------|----------------|---------|
| Age, year     | 58.5 ± 12.2  | 57.6 ± 13.1   | 59.9 ± 10.8  | 52.8 ± 16.7    | 0.24    |
| Female, N (%) | 58 (58.0%)   | 18 (54.6%)    | 35 (60.3%)   | 5 (55.6%)      | 0.86    |
| Asthma duration, year | 19.1 ± 14.5 | 22.0 ± 16.3 | 18.1 ± 14.0 | 15.1 ± 9.8   | 0.32    |
| Smoking status (Current/Ex/Never) | 12/51/37 | 6/19/8 | 6/27/25 | 0/5/4 | 0.19 |
| Pack-years    | 5.5 (0–22.7) | 8.3 (0.1–23.3) | 5.2 (0–24.5) | 2.3 (0–8.0) | 0.24 |
| Body mass index, kg/m² | 25.5 ± 5.0 | 25.3 ± 4.6 | 25.3 ± 5.3 | 27.0 ± 4.7 | 0.63 |
| Daily ICS dose, μg | 1629 ± 510 | 1779 ± 548 | 1532 ± 482 | 1700 ± 450 | 0.08 |
| Maintenance OCS use, N (%) | 37 (37.0%) | 10 (30.3%) | 20 (34.5%) | 7 (77.8%) | 0.03 |
| Atopy, N (%)  | 61 (61.0%)  | 18 (54.6%)    | 37 (63.8%)   | 6 (66.7%)      | 0.64    |
| ACT           | 21.0 (17.0–23.0) | 21.0 (17.5–23.0) | 21.0 (15.8–23.0) | 21.0 (16.5–25.0) | 0.71 |
| AQLQ          | 5.5 (4.8–6.3) | 5.5 (4.8–6.2) | 5.5 (5.0–6.3) | 6.1 (4.3–6.6) | 0.89 |

| Biomarkers |          |            |            |              |         |
|------------|----------|------------|------------|--------------|---------|
| Blood eosinophil, cells/μL | 218 (84–479) | 83 (38–126) | 370 (145–627) | 476 (250–577) | <0.001 |
| Blood neutrophil, cells/μL | 4575 (3231–6005) | 5551 (3568–6576) | 4255 (3110–5616) | 3271 (2787–6165) | 0.19 |
| Total serum IgE, IU/mL | 164 (58–402) | 114 (24–365) | 189 (60–419) | 220 (94–385) | 0.28 |
| Sputum eosinophil, % | 6.8 (0.8–29.6) | 0.8 (0.2–2.2) | 1.8 (2.5–36.8) | 2.13 (6.6–38.6) | <0.001 |
| FENO, ppb | 27.5 (17.0–47.5) | 15.0 (10.0–19.0) | 37.0 (24.8–51.3) | 91.0 (74.5–186.0) | <0.001 |

| Pulmonary function test |          |            |            |              |         |
|-------------------------|----------|------------|------------|--------------|---------|
| FEV₁, % predicted      | 91.6 ± 19.2 | 91.4 ± 18.0 | 91.5 ± 19.7 | 92.9 ± 22.1 | 0.98    |
| FEV₁/FVC, %            | 66.4 ± 12.7 | 67.3 ± 13.9 | 65.7 ± 11.9 | 67.8 ± 14.4 | 0.80    |

| Comorbidities |          |            |            |              |         |
|---------------|----------|------------|------------|--------------|---------|
| AERD, N (%)   | 13 (13.0%) | 8 (24.2%) | 3 (5.2%) | 2 (22.2%) | 0.02    |
| Allergic rhinitis, N (%) | 49 (49.0%) | 13 (39.4%) | 31 (53.5%) | 5 (55.6%) | 0.40 |
| LMS           | 3.0 (0–9.0) | 0 (0–3.0) | 6.5 (1.8–12.0) | 6.0 (3.0–12.5) | <0.001 |
| Nasal poly, N (%) | 25 (25%) | 1 (3.0%) | 21 (36.2%) | 3 (33.3%) | <0.001 |
| FSSG          | 8.0 (3.0–14.0) | 8.0 (4.0–15.5) | 8.0 (3.0–14.3) | 3.0 (1.0–10.5) | 0.39 |
| SDS           | 38.0 (32.0–46.0) | 41.0 (33.0–47.5) | 37.5 (31.0–45.3) | 45.0 (31.0–54.5) | 0.43 |

**Notes**: Data are shown as the mean ± standard deviation, median (interquartile range), or number (%). P-values were obtained using a chi-square test, one-way analysis of variance, or the Kruskal–Wallis test, as appropriate. *Equivalent to budesonide dose.

**Abbreviations**: ACT, asthma control test; AERD, aspirin-exacerbated respiratory disease; AQLQ, asthma quality of life questionnaire; FENO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroids; LMS, Lund–Mackay score; OCS, oral corticosteroids; FSSG, frequency scale for the symptoms of GERD; SDS, self-reported depression scale.

Journal of Asthma and Allergy 2020:13
inflammation measured based on induced sputum and FENO in asthmatic patients is known to exhibit temporal oscillations. Therapeutic strategies targeting type 2 inflammation in asthmatic patients may be beneficial if they stabilize both the amplitude and variability of eosinophilic airway inflammation over time; therefore, longitudinal measurement of FENO is important for monitoring the inflammatory status of the asthmatic airways.

We previously reported the presence of a phenotype of severe asthma with frequent exacerbations and that only FENO levels at baseline are significantly associated with exacerbation status during the 3-year follow-up period among several type 2 biomarkers.

However, long-term assessment of FENO would be more meaningful than baseline assessment alone, and few studies have evaluated the annual changes in FENO. In the present study, persistently high FENO levels were clearly associated with the development of exacerbations. Persistently high FENO levels suggest that uncontrolled eosinophilic airway inflammation still exists despite treatment with high-dose ICS; therefore, use of biologics such as anti-IgE, anti-IL-5, and IL-4R antibodies should be considered for such patients. On the other hand, annual FENO levels in the intermediate group were highly variable despite the patients receiving high-dose ICS therapy. Intraday or daily variation in FENO has been reported to provide useful

---

**Figure 2** Changes in FENO over a 3-year follow-up period.
information about asthma control and the risk of future exacerbations. The present results substantially extend these findings by showing that FENO levels could fluctuate annually in patients with severe asthma in relation with the development of exacerbations.

In healthy individuals, Ekroos et al reported that a change of 30–35% or more in FENO levels within the interval of 1 to 3 weeks should be considered abnormal and proposed this value as a cutoff for significant variation in FENO level. De Laurentiis et al investigated the variation in FENO level over 1 year in patients with chronic obstructive pulmonary disease (COPD), and reported that the CV of FENO was significantly associated with exacerbation rate, but not with baseline FENO levels and degree of airflow limitation. In this study, the cutoff for FENO variability was set at 40% based on the upper limit of the 95% CI of the mean of the entire COPD group. In another study on long-term variation in FENO in lung transplant recipients, Antus et al reported that a variation in FENO levels of more than 30% during 2 years of follow-up was a specific marker of acute infection. Furthermore, Stern et al investigated daily FENO values over 192 days in atopic asthmatic children and found that fluctuations in FENO values were correlated over time scales of more than a month (long-range correlation). They also revealed that the day-by-day cross-correlation of FENO values and symptom scores was stronger in subjects with moderate or severe exacerbations.

In the present study, we found that high variability in annual FENO was associated with the development of exacerbations in the subset (intermediate group) of adults with severe asthma. Taken together, large variability in FENO levels within a relatively long-term period appears to be associated with exacerbation events in lung diseases. Such variation in FENO levels may reflect the instability and reduced adaptive capacity of the airways to changing environmental conditions.

ICS or OCS treatment is a major factor in reducing FENO levels as well as its long-term variability. This issue may not largely influence our findings because all subjects received high-dose ICS with good adherence and 37% of the subjects were on systemic corticosteroids. Indeed, 77.8% of subjects in the sustained FENO high group were on daily OCS treatment, and the high CV intermediate group tended to take higher amounts of ICS than the low CV intermediate group. Anti-IL-4R antibody has also been shown to reduce FENO levels, but anti-IL-4R antibody was not administered to the subjects because of its clinical unavailability in Japan during the study period. Therefore, the FENO levels in the present study reflect the pathological status of severe asthma despite intensive treatment with corticosteroids. Persistence of high FENO levels and high variability would be a good indication

![Figure 3](image-url) **Figure 3** Box plots of exacerbation frequencies over 3 years. The p-values were obtained using the Kruskal–Wallis test with a post-hoc Dunn’s multiple comparison test.

![Figure 4](image-url) **Figure 4** Kaplan–Meier curves for exacerbation-free survival. The intermediate group was divided into two groups, and four groups were compared.
to initiate treatment with biologics in patients with severe asthma.

This study has several limitations. First, the sample size may have been small, despite recruitment of subjects from 29 affiliated hospitals/pulmonary clinics. However, we intentionally focused on severe asthmatics who had been managed by respiratory physicians, and all subjects were carefully followed with a low dropout rate. Second, FENO level was measured only once per year, which made it difficult to determine the causal relationship between variation in FENO levels and asthma exacerbation. As discussed above, FENO can fluctuate on an intraday or daily basis. However, such highly frequent FENO measurement is not realistic in current clinical practice, and our findings suggest that longitudinal FENO assessment on an annual basis can also provide important information on the status of severe asthma. On the other hand, more frequent assessment of FENO, eg, on a monthly basis, might be able to evaluate fluctuation of FENO levels more precisely, despite such data was unavailable due to the protocol of the present cohort study.

| Table 2 Characteristics of Subjects in the Low CV and High CV Intermediate Groups at Baseline |
|----------------------------------------|----------------------------------------|------------------|
| **Demographics**                       | **Low CV**                             | **High CV**      |
| (n = 29)                               | (n = 29)                               | P-value          |
| Age, year                              | 61.1 ± 12.6                            | 58.7 ± 8.8       | 0.39 |
| Female, N (%)                          | 20 (69.0%)                             | 15 (51.7%)       | 0.18 |
| Asthma duration, year                  | 21 ± 16.0                              | 15.2 ± 11.2      | 0.11 |
| Smoking status (Current/Ex/Never)      | 4/9/16                                 | 2/18/9           | 0.06 |
| Pack-years                             | 0 (0–16.0)                             | 11.0 (0–37.5)    | 0.04 |
| Body mass index, kg/m²                 | 24.6 ± 3.6                             | 26.1 ± 6.6       | 0.31 |
| Daily ICS dose, μg                     | 1412 ± 444                             | 1653 ± 495       | 0.06 |
| Maintenance OCS use, N (%)             | 9 (31.0%)                              | 11 (37.9%)       | 0.58 |
| Atopy, N (%)                           | 15 (51.7%)                             | 22 (75.9%)       | 0.05 |
| ACT                                    | 21.0 (18.5–23.0)                       | 20.0 (14.5–23.0) | 0.20 |
| AQOL                                   | 5.6 (5.2–6.5)                          | 5.4 (4.7–6.1)    | 0.14 |
| **Biomarkers**                         | **Low CV**                             | **High CV**      |
| Blood eosinophil, cells/μL            | 389 (145–593)                          | 332 (144–678)    | 0.69 |
| Blood neutrophil, cells/μL            | 4522 (3182–6096)                       | 3994 (3078–5496) | 0.39 |
| Total serum IgE, IU/mL                | 170 (59–378)                           | 194 (81–501)     | 0.67 |
| Sputum eosinophil, %                  | 14.2 (2.0–27.9)                        | 27.6 (4.0–38.8)  | 0.31 |
| FENO, ppb                              | 31.0 (24.0–43.0)                       | 42.0 (28.0–64.5) | 0.19 |
| **Pulmonary function test**           | **Low CV**                             | **High CV**      |
| FEV₁, % predicted                     | 94.1 ± 18.7                            | 88.2 ± 20.7      | 0.26 |
| FEV₁/FVC, %                           | 65.6 ± 12                              | 65 ± 12.6        | 0.84 |
| **Comorbidities**                     | **Low CV**                             | **High CV**      |
| AERD (%)                               | 2 (6.9%)                               | 1 (3.5%)         | 0.55 |
| Allergic rhinitis, N (%)               | 15 (51.7%)                             | 16 (55.2%)       | 0.79 |
| LMS                                    | 7.0 (2.0–10.0)                         | 6.0 (1.0–12.0)   | 0.80 |
| Nasal polyp, N (%)                     | 12 (41.4%)                             | 9 (31.0%)        | 0.41 |
| FSSG                                   | 7 (1–14)                               | 9 (6–15.5)       | 0.07 |
| SDS                                    | 32.0 (31.0–40.0)                       | 42.0 (33.5–48.5) | 0.01 |

Notes: Data are shown as the mean ± standard deviation, median (interquartile range), or number (%). P-values were obtained using a chi-square test, Student’s t-test, or the Mann–Whitney U-test, as appropriate. *Equivalent to budesonide dose.

Abbreviations: ACT, asthma control test; AERD, aspirin-exacerbated respiratory disease; AQOL, asthma quality of life questionnaire; FENO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroids; LMS, Lund–Mackay score; OCS, oral corticosteroids; FSSG, frequency scale for the symptoms of GERD; SDS, self-reported depression scale.
Conclusion
Persistence of FENO level above 50 ppb over the years and the presence of large variations in FENO levels were associated with the development of exacerbations in patients with severe asthma. The findings of the present study emphasize the importance of longitudinal assessment of FENO levels for the management of severe asthma. Further studies on the mechanism of the variation in FENO levels and its association with exacerbations are required in the future.

Abbreviations
ICS, inhaled corticosteroids; FENO, fractional exhaled nitric oxide; iNOS, inducible nitric oxide synthase; IL, interleukin; Hi-CARA, Hokkaido-based Investigative Cohort Analysis for Refractory Asthma; ATS, American Thoracic Society; CV, coefficient of variation; CI, confidence interval; OCS, oral corticosteroids.

Data Sharing Statement
The data sets analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics Approval and Informed Consent
Conducting this study was ethically approved by the Institutional Review Board of Hokkaido University Hospital (reference number: 009-0025). This study was approved by the ethics committees of all hospitals, and all subjects provided written informed consent. This study was registered in the University Hospital Medical Information Network Center Clinical Trials Registry system (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000003917).

Acknowledgments
The authors thank Professor Elizabeth Juniper for approving the use of the Asthma Quality of Life Questionnaire; Hideka Ashikaga, Ayako Kondo, and Yuko Takagi of the

---

**Table 3** Factors Associated with Exacerbations in the Intermediate Group

| Variable  | Hazard Ratio (95% CI) | P-value |
|-----------|----------------------|---------|
| CV of FENO | 6.01 (1.09–29.29)     | 0.04    |

**Exacerbation Frequency**

| Variable  | Rate Ratio (95% CI) | P-value |
|-----------|---------------------|---------|
| CV of FENO | 7.76 (2.32–26.15)   | 0.001   |

Notes: The hazard ratio was derived from the multivariate Cox proportional hazards model, and the rate ratio was derived from the multivariate Poisson regression model. Both models were adjusted for age, sex, body mass index, pack-years, blood eosinophil count, and FENO at baseline.

Abbreviations: CV, coefficient of variation; FENO, fractional exhaled nitric oxide.
Central Office of Hokkaido Medical Research Institute for Respiratory Disease; and the staff of Exam Co., Ltd. for their assistance in completing this work.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

The Hokkaido Severe Asthma Cohort Study or the Hokkaido-based Investigative Cohort Analysis for Refractory Asthma (HI-CARAT) is supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (24249049 to MN, 26461151 to SK) and research grants from the Japan Allergy Foundation, AstraZeneca, and KYORIN.

**Disclosure**

MS reports grants from AstraZeneca, grants from Novartis, and grants from GlaxoSmithKline, outside the submitted work. MN reports grants from AstraZeneca, grants from KYORIN, grants from MSD, and grants from the Japan Allergy Foundation, during the conduct of the study. SK reports grants from AstraZeneca, grants from Novartis, grants from Boehringer-Ingelheim, and grants from KYORIN, outside the submitted work. The authors report no other potential conflicts of interest for this work.

**References**

1. Global initiative for asthma [homepage on the Internet]. Fontana: Global Strategy for Asthma Management and Prevention; 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-with.pdf. Accessed June 15, 2020.

2. Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy*. 2017;47(2):161–175.

3. Konno S, Taniguchi N, Makita H, et al. Distinct phenotypes of smokers with fixed airflow limitation identified by cluster analysis of severe asthma. *Ann Am Thorac Soc*. 2018;15(1):33–41.

4. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med*. 2005;171(8):912–930.

5. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. *Am J Physiol Lung Cell Mol Physiol*. 2015;308(2):L130–L140.

6. Heffler E, Carpagnano GE, Favero E, et al. Fractional exhaled nitric oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). *Multidiscip Respir Med*. 2020;15(1):36.

7. Silkoif PF, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. *J Allergy Clin Immunol*. 2005;116(6):1249–1255.

8. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. *Lancet Respir Med*. 2015;3(4):290–300.

9. Ichinose M, Sugiyama H, Yamagata S, Koai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. *Am J Respir Crit Care Med*. 2000;162(2 Pt 1):701–706.

10. Dweik RA, Boggs PB, Erurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602–615.

11. Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. *Lancet Respir Med*. 2018;6(1):29–39.

12. Kimura H, Konno S, Makita H, et al. Prospective predictors of exacerbation status in severe asthma over a 3-year follow-up. *Clin Exp Allergy*. 2018;48(9):1137–1146.

13. Kimura H, Konno S, Nakamura Y, et al. Sinus computed tomographic findings in adult smokers and non-smokers with asthma. Analysis of clinical indices and biomarkers. *Ann Am Thorac Soc*. 2017;14(3):332–341.

14. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med*. 2000;162(6):2341–2351.

15. ChungKF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43(2):343–373.

16. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant*. 2013;48(3):452–458.

17. Jones SL, Kinnison J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. *Am J Respir Crit Care Med*. 2001;164(5):738–743.

18. Roberts G, Hurley C, Bush A, Lack G. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax*. 2004;59(9):752–756.

19. Pijnenburg MW, Bukker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. *Am J Respir Crit Care Med*. 2005;172(7):831–836.

20. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med*. 2005;172(4):453–459.

21. Khartonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. *Am J Respir Crit Care Med*. 1996;153(1):454–457.

22. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently non- eosinophilic. *Am J Respir Crit Care Med*. 2012;185(6):612–619.

23. van der Valk RJ, Baraldí E, Sterm G, Frey U, de Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. *Allergy*. 2012;67(2):265–271.

24. Saito J, Gibeson D, Macedo F, Menzies-Gow A, Bhavsar PK, ChungKF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. *Eur Respir J*. 2014;43(2):474–484.
25. Ekroos H, Tuominen J, Sovijarvi AR. Exhaled nitric oxide and its long-term variation in healthy non-smoking subjects. *Clin Physiol*. 2000;20(6):434–439.

26. de Laurentiis G, Maniscalco M, Cianciulli F, et al. Exhaled nitric oxide monitoring in COPD using a portable analyzer. *Pulm Pharmacol Ther*. 2008;21(4):689–693.

27. Antus B, Csiszer E, Czebe K, Horvath I. Pulmonary infections increase exhaled nitric oxide in lung transplant recipients: a longitudinal study. *Clin Transplant*. 2005;19(3):377–382.

28. Stern G, de Jongste J, van der Valk R, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. *J Allergy Clin Immunol*. 2011;128(2):293–300.

29. Sinha A, Lutter R, Xu B, et al. Loss of adaptive capacity in asthmatic patients revealed by biomarker fluctuation dynamics after rhinovirus challenge. *Elife*. 2019;8:e47969.

30. Shome GP, Starnes JD 3rd, Shearer M, et al. Exhaled nitric oxide in asthma: variability, relation to asthma severity, and peripheral blood lymphocyte cytokine expression. *J Asthma*. 2006;43(2):95–99.